Silo Pharma

What Silo Pharma does

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company incorporated in Florida in 2020 and publicly traded on the Nasdaq Capital Market under the ticker SILO. The company is developing novel therapeutics for underserved central nervous system conditions, with a pipeline consisting of SPC-15 (a pre-IND intranasal serotonin 4 receptor agonist for prophylactic PTSD treatment), SP-26 (a subcutaneous time-released ketamine implant for fibromyalgia and chronic pain, preclinical), SPC-14 (a preclinical Alzheimer's candidate), and a recently filed provisional patent for ibogaine-based therapeutics targeting traumatic brain injury. Silo pursues the streamlined 505(b)(2) FDA approval pathway and licenses core intellectual property exclusively from Columbia University, with granted US Patent No. 12,239,614 (March 2025), a Japan Patent Office Notice of Allowance, and an intent-to-grant from the European Patent Office.

The company's technology platform centers on a patented intranasal nose-to-brain drug delivery system designed to bypass the blood-brain barrier, providing direct CNS drug concentration with optimized safety. In April 2026, Silo Pharma expanded beyond pure-play biopharma by acquiring the assets of Qwikagents.ai and forming a wholly-owned AI subsidiary that offers personal AI agents — accessible via Telegram, Slack, and Discord — on a subscription basis at $14-72 per month, with initial support for the OpenClaw agent framework. The company has also launched a Digital Assets Treasury Program involving cryptocurrency holdings and tokenized real-world assets on the Solana blockchain.

Silo Pharma is currently pre-revenue from pharmaceutical operations, reporting only $0.02M in Q1 2026 revenue with a deeply negative net margin of 5,870.83%. The company has raised approximately $8.6M through four registered direct and public offerings in 2024-2025 via H.C. Wainwright & Co. as exclusive placement agent. Following a 1-for-15 reverse stock split effective June 2, 2026, the company had approximately 1.084 million shares outstanding and a market capitalization of approximately $6.96M, with a current ratio of 9.65 indicating a cash-rich balance sheet. Go-to-market for pharmaceuticals is entirely pre-commercial; marketing and distribution are oriented toward institutional investors through press releases, the H.C. Wainwright Annual Global Investment Conference, and an investor relations website. Leadership includes founder and CEO Eric Weisblum, CFO Daniel Ryweck (CPA), and VP of R&D Dr. James Kuo (former Pfizer and HealthCare Ventures executive).

Name

Silo Pharma

Legal name

Silo Pharma, Inc.

Website

https://silopharma.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing intranasal and implant CNS therapeutics for PTSD, fibromyalgia, Alzheimer's, and TBI through the 505(b)(2) pathway, with core IP licensed from Columbia University. It also operates a newly acquired AI agent subsidiary, QwikAgents, targeting the consumer/SMB market via subscription.

Ownership category

akta.pro rank

Product category

CNS Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• CNS therapeutics development
• Biopharmaceutical drug pipeline
• Intranasal drug delivery
• Psychedelic therapeutics research
• Fibromyalgia chronic pain

Headquarters

HQ city

Englewood Cliffs

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Development and Licensing: As a developmental-stage biopharmaceutical company, Silo Pharma does not currently generate revenue. The company is focused on developing novel therapeutics for underserved conditions including PTSD, fibromyalgia, and Alzheimer's disease through the 505(b)(2) regulatory pathway. Revenue would potentially be generated through product sales, licensing deals, or partnerships upon successful FDA approval and commercialization.
2. AI Agent Services (QwikAgents): Silo Pharma launched an AI subsidiary to operate the Qwikagents.ai platform, targeting the AI agent market projected to reach $47-53 billion by 2030 with 43-50% annual growth. AI agents are offered at $14-72/month, creating a new revenue stream for the company alongside its pharmaceutical operations.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics for underserved CNS conditions, including the lead candidate SPC-15, an intranasal 5-HT4 receptor agonist for prophylactic PTSD treatment, the SP-26 ketamine implant for fibromyalgia and chronic pain, and SPC-14 for Alzheimer's disease. The company also operates a QwikAgents AI subsidiary offering subscription-based personal AI agents accessible through messaging platforms. All pharmaceutical assets are currently pre-commercial or pre-IND.

Product overview

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company with two distinct operational segments. The biopharmaceutical division centers on a pipeline of novel therapeutic compounds including SPC-15 (intranasal 5-HT4 receptor agonist for PTSD, pre-IND), SP-26 (ketamine implant for fibromyalgia, preclinical), and SPC-14 (Alzheimer's treatment, preclinical), developed in collaboration with academic institutions like Columbia University. The company also operates QwikAgents, an AI subsidiary offering personal AI agents accessible through Telegram, Slack, and Discord, positioning itself as a provider of digital workforce solutions. Additionally, Silo Pharma maintains a digital assets treasury program investing in cryptocurrency and tokenized real-world assets on the Solana blockchain.

Differentiator

Problem solved

Functional benefit

Brands

• QwikAgents: AI subsidiary platform offering personal AI agents that work 24/7, supporting various AI agent frameworks including OpenClaw, with subscription plans ranging from $14-72/month.

Products and services

• SPC-15 Novel intranasal serotonin 4 (5-HT4) receptor agonist designed as a prophylactic treatment for stress-induced affective disorders including PTSD. Features a patented nose-to-brain delivery system that bypasses the blood-brain barrier, providing direct and heightened drug concentration in the brain with faster therapeutic onset and optimized patient safety. Currently in pre-IND stage.
• SP-26

Quantifiable outcome

• SPC-15 maintained stability through 9 months of real-time testing under IND-enabling conditions
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Qwikagents.aicoreTechnology or Integration · 22 April 2026Silo Pharma acquired assets of Qwikagents.ai and formed a new AI subsidiary to operate the platform. The AI agent platform enables personal AI agents that work 24/7 through apps like Telegram, Slack, or Discord. The company cited market projections estimating the AI agent sector will reach $47-53 billion by 2030 with 43-50% annual growth. The new subsidiary is expected to create an additional revenue stream.
• AllucentcoreImplementation/ SI/ Consulting Partner · 17 November 2025Silo Pharma selected Allucent, a global clinical research organization, to support the preparation and planned submission of an Investigational New Drug application to the FDA for SPC-15, an intranasal prophylactic treatment for PTSD. The company expects to submit the IND in 2026 and commence first-in-human Phase 1 clinical trials following FDA approval. GLP toxicology and drug-device study data was anticipated in early 2026.
• Columbia UniversitycoreStrategic or Co-development PartnerExclusive licensing agreement with Columbia University for intellectual property related to SPC-15 (serotonin 4 receptor agonist for stress-related disorders) and other therapeutic candidates. The licensing agreement enables Silo Pharma to pursue the 505(b)(2) regulatory pathway for faster approval. Columbia University's CELA (presumably Center for Experimental Drugs and Therapeutics or similar) collaboration supports drug development.

Scale indicators18 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ATAI Life Sciences: Clinical-stage biopharma developing psychedelic and non-psychedelic therapies for mental health disorders. Direct peer in psychedelic CNS drug development with a portfolio approach across multiple CNS indications similar to Silo's.
• GH Research: Clinical-stage biopharma developing novel psychedelic therapies for psychiatric and neurological disorders. Directly comparable as a small-cap CNS/psychedelic-focused developer with similar regulatory and clinical milestones.
• Cybin: Clinical-stage psychedelic therapeutics company developing deuterated tryptamine-based therapies for mental health conditions. Direct peer in psychedelic CNS drug development with comparable pipeline scope and target indications.
• Compass Pathways: Mental health care company developing psilocybin therapy for treatment-resistant depression. Direct peer in psychedelic CNS drug development with comparable regulatory pathway focus and clinical-stage pipeline.
• Mind Medicine (MindMed): Clinical-stage psychedelic CNS biopharma developing psychedelic-inspired therapies for mental health and CNS conditions. Directly comparable to Silo in pipeline category (CNS, psychedelic-adjacent) and target indications including anxiety/PTSD-like conditions, with a similarly small market cap and early clinical stage.
• Tonix Pharmaceuticals: Clinical-stage CNS biopharma developing therapies for PTSD, fibromyalgia, and CNS disorders. Direct peer in indication overlap (PTSD, fibromyalgia) and CNS development focus, with a small-cap profile similar to Silo's.

Broad incumbents

• Sage Therapeutics: Commercial-stage CNS biopharma with FDA-approved CNS therapies (Zulresso, Zurzuvae). Comparable in CNS/neurology focus and 505(b)-style regulatory navigation, but a more established player with commercial products and a broader pipeline.
• Acadia Pharmaceuticals: Commercial-stage CNS biopharma focused on neurological and psychiatric disorders including Parkinson's disease psychosis and Rett syndrome. Comparable in CNS therapeutic focus with a more mature commercial footprint than Silo.

Emerging players

• Bionomics Limited: Clinical-stage biopharma developing CNS therapies with a specific focus on PTSD and anxiety. Directly comparable in PTSD indication focus, with a small-cap clinical-stage profile similar to Silo's.
• Tryp Therapeutics: Clinical-stage psychedelic drug development company with overlapping CNS/psychedelic thesis and previously led by Dr. James Kuo (Silo's VP of R&D). Comparable in psychedelic CNS pipeline focus and stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SiloPharma
• Facebookfacebook.com/SiloPharma
• LinkedInlinkedin.com/company/silopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Silo Pharma